Legal Opinion
Ranbaxy Laboratories, Ltd. v. Leavitt
District Court, District of Columbia
Decided May 1, 2006No. Civil Action 05-1838 (RWR)PublishedCited by 3 opinions
1Opinion of the Court
MEMORANDUM OPINION
ROBERTS, District Judge.
Ranbaxy Laboratories Limited 1 (“Ran-baxy”) and IVAX Pharmaceuticals, Inc. (“IVAX”) each sued the Food and Drug Administration (“FDA”) under 5 U.S.C. § 706 claiming that the FDA improperly nullified Ranbaxy and IVAX’s rights to a 180-day period of exclusive marketing of a generic drug. Ranbaxy and IVAX moved for summary judgment against the FDA seeking to vacate the FDA’s decision. The FDA filed a cross-motion for summary judgment. Because the FDA failed to give full effect to the unambiguous intent of Congress, Ranbaxy and IVAX’s motions for summary…
2Cases cited16 opinions
- Anderson v. Liberty Lobby, Inc.Supreme Court of the United States · 1986
- Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 1984
- Connecticut National Bank v. GermainSupreme Court of the United States · 1992
- National Railroad Passenger Corporation v. Boston & Maine Corp.Supreme Court of the United States · 1992
- In Re Barr Laboratories, Inc.Court of Appeals for the D.C. Circuit · 1991
11 more not listed; retrieve them via the Exa API.
3Cited by3 opinions
- Failing v. Washington State Liquor and Cannabis BoardDistrict Court, E.D. Washington · 2020
- Ipsen Biopharmaceuticals, Inc. v. BecerraDistrict Court, District of Columbia · 2023
- Watson Laboratories, Inc. v. SebeliusDistrict Court, District of Columbia · 2012